Rapid Review Quiz: COVID-19 Updates

Michael Stuart Bronze, MD


September 28, 2022

A recent investigation found that nirmatrelvir/ritonavir (Paxlovid) treatment reduced the risk of dying from COVID-19 by 79% among at-risk patients aged ≥ 65 years; it also decreased hospitalizations by 73%. Data are less clear among patients aged 40-64 years. An Israeli study revealed that neither the rate of hospitalization nor the risk for death due to COVID-19 was significantly lower, whereas others suggest that there may be benefit. Also, the survival and hospitalization benefits extend to those who have not had vaccination against COVID-19. Finally, a recent meta-analysis determined that COVID-19 patients receive no significant benefit from convalescent plasma therapy.

Researchers examined information from electronic medical records provided by Clalit Health Services, a healthcare organization that covers about 52% of the total population of Israel and almost two thirds of older adults in that country. More than 30,000 COVID-19 patients in Israel were treated with nirmatrelvir/ritonavir. The team evaluated hospitalization and death data for at-risk COVID-19 patients aged ≥ 40 years between January 9, 2022, and March 31, 2022, when the Omicron variant was the dominant strain.

Learn more about nirmatrelvir/ritonavir.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.